BCL6B and cervical carcinoma: Conversely, downregulated BCL6B expression is observed in bladder urothelial carcinoma, invasive breast cancer, chromophobe renal carcinoma, renal papillary cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, endometrial cancer, and cervical cancers.